Biotricity (US:BTCY) Globenewswire·2025-11-14 21:00Core Insights - Biotricity Inc. reported a 19% increase in revenue for Q2 FY26, reaching $3.9 million compared to $3.3 million in the same period last year, indicating strong growth in its Technology-as-a-Service (TaaS) model [7] - The company achieved a gross margin of 81.9%, up from 75.3% year-over-year, reflecting operational efficiencies and an expanding recurring revenue base [7] - Net loss improved significantly to $0.77 million, or $0.03 per share, from a net loss of $1.7 million, or $0.07 per share, marking a 53.3% reduction in losses [7] Financial Highlights - Recurring TaaS Technology Fees rose by 4.2% year-over-year to $3.5 million, constituting 88.7% of total revenue for Q2 FY26 [7] - The company maintained a strong customer retention rate, attributed to high-quality services that prioritize diagnostic accuracy and user-friendliness [7] - Biotricity is making progress in securing regulatory approvals in key international markets, including Canada, Saudi Arabia, and Argentina, which will facilitate broader distribution [7] Operational Highlights - The company is focusing on enhancing operational efficiency through proprietary AI-driven automation, which is expected to sustain margins and accelerate growth [2] - Biotricity is expanding its market presence in the U.S. by engaging with thousands of cardiologists and forming strategic alliances with major Group Purchasing Organizations (GPOs) that represent 90% of U.S. hospitals [7] - The launch of the Biocore Pro cardiac monitoring device and large-scale pilots in leading hospital networks demonstrate the company's capability to scale its technology and impact [2]